Article Text

Download PDFPDF

Real-world health services utilisation and outcomes after BRCA1 and BRCA2 testing in Ontario, Canada: the What Comes Next Cohort Study protocol
  1. Fahima Dossa1,2,3,
  2. Maria C Cusimano3,4,
  3. Rinku Sutradhar3,5,
  4. Kelly Metcalfe6,
  5. Tari Little2,
  6. Jordan Lerner-Ellis7,8,
  7. Andrea Eisen9,
  8. Wendy S Meschino10,11,
  9. Nancy N Baxter1,2,3,5
  1. 1 Division of General Surgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada
  2. 2 Department of Surgery, St Michael’s Hospital, Toronto, Ontario, Canada
  3. 3 Institute for Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada
  4. 4 Department of Obstetrics and Gynaecology, University of Toronto, Toronto, Ontario, Canada
  5. 5 Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada
  6. 6 Lawrence S Bloomberg Faculty of Nursing, University of Toronto, Toronto, Ontario, Canada
  7. 7 Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
  8. 8 Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada
  9. 9 Sunnybrook Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
  10. 10 Department of Molecular Genetics, North York General Hospital, Toronto, Ontario, Canada
  11. 11 Department of Paediatrics, University of Toronto, Toronto, Ontario, Canada
  1. Correspondence to Dr. Nancy N Baxter; BaxterN{at}smh.ca

Abstract

Introduction Women who have pathogenic mutations in the BRCA1 and BRCA2 genes are at greatly increased risks for breast and ovarian cancers. Although risk-reduction strategies can be undertaken by these women, knowledge regarding the uptake of these strategies is limited. Additionally, the healthcare behaviours of women who receive inconclusive test results are not known. This study protocol describes the creation of a retrospective cohort of women who have undergone genetic testing for BRCA1 and BRCA2, linking genetic test results with administrative data to quantify the uptake of risk-reduction strategies and to assess long-term cancer and non-cancer outcomes after genetic testing.

Methods and analysis Approximately two-thirds of BRCA1 and BRCA2 testing in Ontario, Canada is performed at North York General Hospital (NYGH) and Mount Sinai Hospital (MSH), Toronto. We will use registries at these sites to assemble a cohort of approximately 17 000 adult women who underwent BRCA1 and BRCA2 testing from January 2007 to April 2016. Trained chart abstractors will obtain detailed information for all women tested over this period, including demographics, personal and family cancer histories and genetic test results. We will link these data to provincial administrative databases, enabling assessment of healthcare utilisation and long-term outcomes after testing. Study outcomes will include the uptake of breast cancer screening and prophylactic breast and ovarian surgery, cancer incidence and mortality and incidence of non-cancer health outcomes, including cardiovascular, osteoporotic and neurodegenerative disease.

Ethics and dissemination This study has been approved by the Research Ethics Boards at NYGH (no 16-0035), MSH (no 13-0124) and Sunnybrook Health Sciences Centre (no 275-2016). We plan to disseminate research findings through peer-reviewed publications and presentations at national and international meetings.

  • genes BRCA1
  • genes, BRCA2
  • breast neoplasms
  • ovarian neoplasms
  • genetic predisposition to disease

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors FD, MCC, RS, KM and NNB contributed to the design of this study. FD, TL, JL-E, AE and WSM participated in the data acquisition. FD, MCC, RS and NNB contributed to developing the analytic plan proposed for this study. FD, TL, JL-E, AE, WSM and NNB were involved in obtaining the ethics approval for this work. FD prepared the first draft of the manuscript. All authors contributed to and approved the final version of the manuscript.

  • Funding This study is conducted with support from the Canadian Breast Cancer Foundation-Ontario Region (no 316528). This study is also supported by the Institute for Clinical Evaluative Sciences (ICES), which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). This study is supported by the American College of Surgeons Resident Research Scholarship awarded to Drs Fahima Dossa and Maria Cusimano.

  • Competing interests None declared.

  • Patient consent Not required.

  • Ethics approval Mount Sinai Hospital, North York General Hospital, Sunnybrook Health Sciences Centre.

  • Provenance and peer review Not commissioned; peer reviewed for ethical and funding approval prior to submission.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.